Prednisone affects inflammation, glucose tolerance, and bone, turnover within hours of treatment in healthy individuals

European Journal of Endocrinology

Volumn 166, Issue 3, 2012, Pages 459-467

  Kauh, Eunkyung ^a   Mixson, Lori ^a   Malice, Marie Pierre ^a   Mesens, Sofie ^b   Ramael, Steven ^b   Burke, Joanne ^a   Reynders, Tom ^c   Van Dyck, Kristien ^c   Beals, Chan ^a   Rosenberg, Elizabeth ^a   Ruddy, Marcella ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SGS Medisearch International NV   (Belgium)

^c MSD Europe   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; GLUCOSE; INSULIN; LIPOPOLYSACCHARIDE; OSTEOCALCIN; PLACEBO; PREDNISONE; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE TURNOVER; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN ALLERGY; TREATMENT DURATION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PREDNISONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857971473     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0751     Document Type: Article

References (34)

1. Schacke H, Docke WD & Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics 2002 96 23-43. (doi:10.1016/S0163-7258(02)00297-8)
2. Vegiopoulos A & Herzig S. Glucocorticoids, metabolism and metabolic diseases. Molecular and Cellular Endocrinology 2007 275 43-61. (doi:10.1016/j.mce.2007.05.015)
3. van Raalte DH, Ouwens DM & Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? European Journal of Clinical Investigation 2009 39 81-93. (doi:10.1111/j.1365-2362.2008.02067.x)
4. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE & Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002 25 583-592. (doi:10.2337/diacare.25.3.583)
5. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M, Kashiwagi A & Yamauchi A. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron. Clinical Practice 2007 105 c54-c57. (doi:10.1159/000097598)
6. Schneiter P & Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. American Journal of Physiology 1998 275 E806-E813.
7. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinology and Metabolism Clinics of North America 2003 32 135-157, vii. (doi:10.1016/S0889- 8529(02)00064-6)
8. De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Medica 2008 99 23-43. (Pubitemid 351518524)
9. Berris KK, Repp AL & Kleerekoper M. Glucocorticoid-induced osteoporosis. Current Opinion in Endocrinology, Diabetes, and Obesity 2007 14 446-450. (doi:10.1097/MED.0b013e3282f15407)
10. Canalis E, Mazziotti G, Giustina A & Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International 2007 18 1319-1328. (doi:10.1007/s00198-007-0394-0)
11. Ton FN, Gunawardene SC, Lee H & Neer RM. Effects of low-dose prednisone on bone metabolism. Journal of Bone and Mineral Research 2005 20 464-470. (doi:10.1359/JBMR.041125)
12. Lems WF, Van Veen GJ, Gerrits MI, Jacobs JW, Houben HH, Van Rijn HJ & Bijlsma JW. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. British Journal of Rheumatology 1998 37 27-33. (doi:10.1093/rheumatology/37.1.27)
13. Godschalk MF & Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. Journal of Bone and Mineral Research 1988 3 113-115. (doi:10.1002/jbmr.5650030117)
14. Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M &Sugimoto T. Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. Journal of Bone and Mineral Metabolism 2008 26 271-278. (doi:10.1007/s00774-007-0821-5)
15. Gram J, Junker P, Nielsen HK & Bollerslev J. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 1998 23 297-302. (doi:10.1016/S8756-3282(98)00097-0)
16. van Staa TP, Leufkens HG & Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis International 2002 13 777-787. (doi:10.1007/s001980200108)
17. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcified Tissue International 2006 79 129-137. (doi:10.1007/s00223-006-0019-1)
18. Schacke H, Berger M, Rehwinkel H & Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Molecular and Cellular Endocrinology 2007 275 109-117. (doi:10.1016/j.mce.2007.05.014)
19. Brideau C, Van Staden C, Styhler A, Rodger IW & Chan CC. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. British Journal of Pharmacology 1999 126 979-988. (doi:10.1038/sj.bjp.0702387)
20. Pacini G & Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Practice & Research. Clinical Endocrinology & Metabolism 2003 17 305-322. (doi:10.1016/S1521-690X(03) 00042-3)
21. Mari A, Pacini G, Murphy E, Ludvik B & Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001 24 539-548. (doi:10.2337/diacare.24.3.539)
22. Waage A & Bakke O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988 63 299-302.
23. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/diacare.27.6.1487)
24. Cameron RG, Black PN, Braan C & Browett PJ. A comparison of the effects of oral prednisone and inhaled beclomethasone dipropionate on circulating leukocytes. Australian and New Zealand Journal of Medicine 1996 26 800-805. (doi:10.1111/j.1445-5994.1996.tb00628.x)
25. Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M &Simon HU. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 1997 52 144-154. (doi:10.1111/j.1398-9995.1997.tb00968.x)
26. Serra-Bonett N, Al Snih S & Rodriguez MA. Effect of low-dose prednisone on leukocyte counts and subpopulations in patients with rheumatoid arthritis. Journal of Clinical Rheumatology 2009 15 148-149. (doi:10.1097/RHU.0b013e3181a3ac2d)
27. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, Norman PS &Lichtenstein LM. Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. Journal of Immunology 1991 146 671-676.
28. Varney V, Gaga M, Frew AJ, De Vos C & Kay AB. The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects. Clinical and Experimental Allergy 1992 22 43-49. (doi:10.1111/j.1365-2222.1992.tb00113.x)
29. Taborda-Barata L, Jacobson M, Walker S, Njuki F, Ying S, Randev P, Durham SR & Kay AB. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clinical and Experimental Allergy 1996 26 68-78. (doi:10.1111/j.1365-2222.1996. tb00058.x)
30. van Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJW, Ackermans MT, Sauerwein HP, Serlie MJ &Diamant M. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011 54 2103-2112. (doi:10.1007/s00125-011-2174-9)
31. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P & Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. Journal of Clinical Endocrinology and Metabolism 2011 96 1789-1796. (doi:10.1210/jc.2010-2729)
32. Civitelli R & Ziambaras K. Epidemiology of glucocorticoid-induced osteoporosis. Journal of Endocrinological Investigation 2008 31 (7 Suppl) 2-6.
33. Ohnaka K, Tanabe M, Kawate H, Nawata H & Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochemical and Biophysical Research Communications 2005 329 177-181. (doi:10.1016/j.bbrc. 2005.01.117)
34. Ohnaka K, Taniguchi H, Kawate H, Nawata H & Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochemical and Biophysical Research Communications 2004 318 259-264. (doi:10.1016/j.bbrc.2004.04.025)